The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b

Journal of Bone and Mineral Research

Volumn 29, Issue 1, 2014, Pages 43-54

  Li, Jau Yi ^a   Walker, Lindsey D ^a   Tyagi, Abdul Malik ^a   Adams, Jonathan ^a   Neale Weitzmann, M ^a,b   Pacifici, Roberto ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

antibody; bone; PTH; SCL; T cells; WNT10B

Indexed keywords

MONOCLONAL ANTIBODY; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG; WNT10B PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE STRUCTURE; BONE TURNOVER; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN; NULL CELL; OSSIFICATION; OSTEOBLAST; PROTEIN SECRETION; STROMA CELL; T LYMPHOCYTE; TRABECULAR BONE;

ANTIBODY; BONE; PTH; SCL; T CELLS; WNT10B;

ANIMALS; ANTIBODIES; BONE AND BONES; BONE DENSITY; FEMALE; GLYCOPROTEINS; MICE; OSTEOBLASTS; OSTEOGENESIS; PARATHYROID HORMONE; T-LYMPHOCYTES; WNT PROTEINS;

EID: 84890893941     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2044     Document Type: Article

References (60)

1. Zaidi M., Skeletal remodeling in health and disease. Nat Med. 2007; 13 (7): 791-801.
2. Calvi LM, Sims NA, Hunzelman JL, et al. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest. 2001; 107 (3): 277-86.
3. Lanske B, Amling M, Neff L, Guiducci J, Baron R, Kronenberg HM., Ablation of the PTHrP gene or the PTH/PTHrP receptor gene leads to distinct abnormalities in bone development. J Clin Invest. 1999; 104 (4): 399-407.
4. Qin L, Raggatt LJ, Partridge NC., Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab. 2004; 15 (2): 60-5.
5. Lindsay R, Cosman F, Zhou H, et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res. 2006; 21 (3): 366-73.
6. Ma YL, Zeng Q, Donley DW, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21 (6): 855-64.
7. Dobnig H, Turner RT., The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997; 138 (11): 4607-12.
8. Dobnig H, Turner RT., Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995; 136 (8): 3632-8.
9. Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, Uchiyama Y, Suda T, Yoshiki S, Takahashi HE., Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone. 1994; 15 (6): 717-23.
10. Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK., Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone. 2008; 42 (4): 806-18.
11. Meng XW, Liang XG, Birchman R, et al. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J Bone Miner Res. 1996; 11 (4): 421-9.
12. Schmidt IU, Dobnig H, Turner RT., Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology. 1995; 136 (11): 5127-34.
13. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC., Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104 (4): 439-46.
14. Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003; 278 (50): 50259-72.
15. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S., Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem. 2005; 280 (50): 41342-51.
16. Tobimatsu T, Kaji H, Sowa H, et al. Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology. 2006; 147 (5): 2583-90.
17. O'Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE. 2008; 3 (8): e2942.
18. Wu X, Pang L, Lei W, et al. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell. 2010; 7 (5): 571-80.
19. Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009; 15 (7): 757-65.
20. Bikle DD, Sakata T, Leary C, et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res. 2002; 17 (9): 1570-8.
21. Yamaguchi M, Ogata N, Shinoda Y, et al. Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. Endocrinology. 2005; 146 (6): 2620-8.
22. Jilka RL., Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007; 40 (6): 1434-46.
23. Kato M, Patel MS, Levasseur R, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol. 2002; 157 (2): 303-14.
24. Bodine PV, Komm BS., Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord. 2006; 7 (1-2): 33-9.
25. Bodine PV, Billiard J, Moran RA, et al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem. 2005; 96 (6): 1212-30.
26. Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8 (5): 751-64.
27. Wan M, Yang C, Li J, et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev. 2008; 22 (21): 2968-79.
28. Li X, Liu H, Qin L, et al. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem. 2007; 282 (45): 33086-97.
29. Terauchi M, Li JY, Bedi B, et al. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab. 2009; 10 (3): 229-40.
30. Keller H, Kneissel M., SOST is a target gene for PTH in bone. Bone. 2005; 37 (2): 148-58.
31. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146 (11): 4577-83.
32. Silvestrini G, Ballanti P, Leopizzi M, et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol. 2007; 38 (4): 261-9.
33. Guo J, Liu M, Yang D, et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab. 2010; 11 (2): 161-71.
34. Kulkarni NH, Halladay DL, Miles RR, et al. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem. 2005; 95 (6): 1178-90.
35. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA., Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010; 95 (4): 1991-7.
36. Drake MT, Srinivasan B, Modder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010; 95 (11): 5056-62.
37. Kramer I, Keller H, Leupin O, Kneissel M., Does osteocytic SOST suppression mediate PTH bone anabolism ? Trends Endocrinol Metab. 2010; 21 (4): 237-44.
38. Kramer I, Loots GG, Studer A, Keller H, Kneissel M., Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. 2010; 25 (2): 178-89.
39. Sims NA., Building bone with a SOST-PTH partnership. J Bone Miner Res. 2010; 25 (2): 175-7.
40. Robling AG, Kedlaya R, Ellis SN, et al. Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in sost-deficient mice. Endocrinology. 2011; 152 (8): 2963-75.
41. Gao Y, Wu X, Terauchi M, et al. T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab. 2008; 8 (2): 132-45.
42. Tawfeek H, Bedi B, Li JY, et al. Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS One. 2010; 5 (8): e12290.
43. Bedi B, Li JY, Tawfeek H, et al. Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH. Proc Natl Acad Sci USA. 2012; 109 (12): E725-33.
44. Bonnet N, Standley KN, Bianchi EN, et al. The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity. J Biol Chem. 2009; 284 (51): 35939-50.
45. Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA. 2005; 102 (9): 3324-9.
46. Bonnet N, Conway SJ, Ferrari SL., Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin. Proc Natl Acad Sci USA. 2012; 109 (37): 15048-53.
47. Cenci S, Toraldo G, Weitzmann MN, et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA. 2003; 100 (18): 10405-10.
48. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013; 28 (1): 2-17.
49. Li JY, Tawfeek H, Bedi B, et al. Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proc Natl Acad Sci USA. 2011; 108 (2): 768-73.
50. Gao Y, Qian W-P, Dark K, et al. Estrogen prevents bone loss through transforming growth factor {beta} signaling in T cells. Proc Natl Acad Sci USA. 2004; 101 (27): 16618-23.
51. Gao Y, Grassi F, Ryan MR, et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest. 2007; 117 (1): 122-32.
52. Stevens JR, Miranda-Carboni GA, Singer MA, Brugger SM, Lyons KM, Lane TF., Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells. J Bone Miner Res. 2010; 25 (10): 2138-47.
53. Ominsky M, Samadfam R, Jolette J, Smith SY, Ke HZ, Boyce RY., Long-term sclerostin antibody treatment in cynomolgus monkeys: sustained improvement in vertebral microarchitecture and bone strength following a temporal increase in cancellous bone formation. Presented at: ASBMR 2012 Annual Meeting; October 2012; Minneapolis, MN.
54. LI X, Niu TQ, Warmington KS, et al. Short- and long-term effects of sclerostin antibody in an ovariectomizzed rat model. Presented at: ASBMR 2012 Annual Meeting; October 2012; Minneapolis, MN.
55. McClung MR, Grauer A, Boonen S, et al. Inhibition of sclerostin with AMG 785 in postmenopausal women with low bone mineral density: phase 2 trial results. Presented at: ASBMR 2012 Annual Meeting; October 2012; Minneapolis, MN.
56. Baron R, Kneissel M., WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013; 19 (2): 179-92.
57. Tian X, Jee WS, Li X, Paszty C, Ke HZ., Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone. 2011; 48 (2): 197-201.
58. Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WS., Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone. 2010; 47 (3): 529-33.
59. Eddleston A, Marenzana M, Moore AR, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res. 2009; 24 (10): 1662-71.
60. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24 (4): 578-88.